St. Jude Medical Reports First Quarter 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/5/2026
- Dow, S&P 500 close at record on AI-linked earnings, Mideast deal hopes
- Caterpillar stock jumps on strong earnings and revenue beat
- Optical component stocks rally on proposed U.S. ban on Chinese tech
- BofA says this memory stock could double. Here are 5 reasons why
- Merck shares rise on big Q2 earnings beat, adjusted FY outlook
- Nutanix to cut 5% of workforce, expects up to $43M in charges
- Opendoor posts Q2 revenue rise as net loss widens year over year
- Walmart dips after Oppenheimer downgrades shares on difficult short-term setup
- Dave & Buster's names CFO Darin Harper as new CEO
- Dow, S&P 500 close at record on AI-linked earnings, Mideast deal hopes
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
St. Jude Medical (STJ) PT Lifted to $82 at Wedbush Following Strong Q1
April 23, 2015 7:55 AM EDTWedbush analyst Tao Levy reiterated an Outperform rating and raised his price target on St. Jude Medical (NYSE: STJ) to $82.00 (from $77.00) following "impressive" Q1 results.
Levy commented, "Impressive 1Q results for St. Jude Medical, driven by CardioMEMS, Atrial Fibrillation, and Neuromodulation; bodes well... More
Credit Suisse Upgrades St. Jude Medical (STJ) to Outperform
April 23, 2015 7:28 AM EDTCredit Suisse upgraded St. Jude Medical (NYSE: STJ) from Neutral to Outperform with a price target of $84.00 (from $74.00) on Bullish LT CardioMEMS view.
Analyst B. Nudell commented, "We're upgrading STJ to Outperform from Neutral given our view that MDT's US ICD... More
St. Jude Medical (STJ) Price Target Lifted to $86 at Needham & Company
April 22, 2015 11:28 AM EDTNeedham & Company analyst Mike Matson reiterated a Strong Buy rating and raised his price target on St. Jude Medical (NYSE: STJ) to $86.00 (from $83.00)
Matson commented, "STJ's 1Q15 revenue and EPS beat consensus. Management raised its 2015 constant currency revenue guidance given better than expected 1Q15 growth and... More
St. Jude Medical (STJ) Tops Q1 EPS by 2c; Guides Q1 EPS to Strong-Side of Views
April 22, 2015 7:16 AM EDTSt. Jude Medical (NYSE: STJ) reported Q1 EPS of $0.93, $0.02 better than the analyst estimate of $0.91. Revenue for the quarter came in at $1.35 billion versus the consensus estimate of $1.32 billion.
Outlook:
St. Jude Medical sees Q2 2015 EPS of $0.99 - $1.01, versus... More
